Core Viewpoint - The company, Olin Bio, is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and optimize its capital structure [2] Group 1: Company Strategy - The company aims to deepen its international strategic layout and increase its global recognition and influence [2] - The initiative is part of a broader effort to strengthen the company's overall competitive capabilities [2] Group 2: Listing Process - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing [2] - Specific details about the H-share listing are yet to be determined [2] - The listing process will require approval from the company's board and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [2]

Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase global recognition, and optimize its capital structure [1] Group 1 - The company aims to deepen its international strategic layout [1] - The initiative is intended to enhance the company's international visibility and influence [1] - The move is part of efforts to strengthen the company's overall competitive strength [1]

证券代码：688319 证券简称：欧林生物 公告编号：2025-048 成都欧林生物科技股份有限公司 关于筹划发行 H 股股票并在香港联合交易所有限公司 上市的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司(以下简称"公司")为深化公司国际化战略 布局，提升国际知名度与影响力，并进一步优化资本结构，增强综合竞争实力， 正在筹划发行境外股份（H 股）并申请在香港联合交易所有限公司（以下简称"香 港联交所"）挂牌上市事宜（以下简称"本次 H 股上市"）。 截至目前，公司正与相关中介机构就本次 H 股上市的相关工作进行商讨，关 于本次 H 股上市的细节尚未确定。根据《中华人民共和国公司法》《中华人民共 和国证券法》《上海证券交易所科创板股票上市规则》《境内企业境外发行证券 和上市管理试行办法》《香港联合交易所有限公司证券上市规则》等相关法律法 规和规范性文件的要求，待确定具体方案后，本次 H 股上市工作尚需提交公司董 事会和股东会审议，并需取得中国证券监督管理委员会、香港联交所和香港证券 ...

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization efforts and optimize its capital structure [1] - The goal of this move is to strengthen the company's overall competitiveness in the market [1]

Group 1 - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international presence and influence [1] - This initiative is part of the company's strategy to deepen its internationalization and optimize its capital structure [1] - The goal is to strengthen the company's overall competitiveness in the market [1]

Core Viewpoint - The company, Olin Bio (688319.SH), is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy, increase global visibility and influence, and further optimize its capital structure to strengthen its overall competitiveness [1] Group 1 - The company is currently in discussions with relevant intermediaries regarding the H-share listing [1] - Details of the H-share listing are yet to be determined [1] - The H-share listing plan requires approval from the company's board and shareholders, as well as necessary filings and approvals from relevant government and regulatory bodies [1]

Group 1 - The company, Olin Bio (688319), announced on September 23 that it is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange [1] - Currently, the company is in discussions with relevant intermediaries regarding the H-share listing process, and specific details have yet to be determined [1]

Core Viewpoint - The company is planning to issue overseas shares (H-shares) and apply for listing on the Hong Kong Stock Exchange [1] Group 1 - The company is currently in discussions with relevant intermediaries regarding the H-share listing [1] - Details of the H-share listing have not yet been finalized [1] - The H-share listing process requires approval from the company's board of directors and shareholders, as well as regulatory approvals from the China Securities Regulatory Commission, Hong Kong Stock Exchange, and the Securities and Futures Commission of Hong Kong [1]

Group 1 - The company received a total government subsidy of RMB 4.64 million for its project on the development and industrialization of a vaccine for methicillin-resistant Staphylococcus aureus [1] - Of the total subsidy, RMB 3.248 million is allocated to the company, while RMB 1.392 million is for the project partner [1] - The government subsidy received by the company is classified as a revenue-related subsidy, and its impact on the company's profit for the current and future years is uncertain until project completion and acceptance [1]

证券日报网讯 9月19日晚间，欧林生物发布公告称，近期，成都欧林生物科技股份有限公司（以下简 称"公司"）"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项目入选四川省2025年第二批省级科技计 划，公司于2025年9月19日收到政府补助款项共计人民币464万元，其中324.8万元为公司所获政府补 助；其余139.2万元为项目合作单位所获政府补助。 （文章来源：证券日报） ...